Total Payments
$584,199
2024 Payments
$24.35
Companies
3
Transactions
142
Medicare Patients
4,463
Medicare Billing
$322,471
Payment Breakdown by Category
Consulting$467,190 (80.0%)
Research$116,985 (20.0%)
Food & Beverage$24.35 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $467,190 | 135 | 80.0% |
| Unspecified | $116,985 | 6 | 20.0% |
| Food and Beverage | $24.35 | 1 | 0.0% |
Payments by Type
General
$467,214
136 transactions
Research
$116,985
6 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Merck Sharp & Dohme Corporation | $467,190 | 135 | $0 (2021) |
| E.R. Squibb & Sons, L.L.C. | $116,985 | 6 | $0 (2023) |
| PROGENICS PHARMACEUTICALS, INC. | $24.35 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $24.35 | 1 | PROGENICS PHARMACEUTICALS, INC. ($24.35) |
| 2023 | $12,460 | 1 | E.R. Squibb & Sons, L.L.C. ($12,460) |
| 2022 | $45,515 | 1 | E.R. Squibb & Sons, L.L.C. ($45,515) |
| 2021 | $267,675 | 61 | Merck Sharp & Dohme Corporation ($244,355) |
| 2020 | $206,615 | 45 | Merck Sharp & Dohme Corporation ($182,305) |
| 2019 | $35,060 | 23 | Merck Sharp & Dohme Corporation ($26,730) |
| 2018 | $16,850 | 10 | Merck Sharp & Dohme Corporation ($13,800) |
All Payment Transactions
142 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 05/21/2024 | PROGENICS PHARMACEUTICALS, INC. | PYLARIFY (Drug) | Food and Beverage | In-kind items and services | $24.35 | General |
| Category: RADIOPHARMACEUTICAL | ||||||
| 01/05/2023 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | — | Cash or cash equivalent | $12,460.00 | Research |
| Study: Phase III Nivo+Ipi vs Placebo in Adjuvant RCC (Part B FA) - A Phase 3 Randomized, Double-Blind Study of Nivolumab Monotherapy or Nivolumab Combined with Ipilimumab vs Placebo in Participants with Localized Renal Cell Carcinoma Who Underwent Radical or Par • Category: Oncology | ||||||
| 01/05/2022 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | — | Cash or cash equivalent | $45,515.00 | Research |
| Study: Phase III Nivo Ipi vs Placebo in Adjuvant RCC - A Phase 3 Randomized, Double-Blind Study of Nivolumab Monotherapy or Nivolumab Combined with Ipilimumab vs Placebo in Participants with Localized Renal Cell Carcinoma Who Underwent Radical or Partial Nephrec • Category: Oncology | ||||||
| 12/07/2021 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $8,820.00 | General |
| Category: ONCOLOGY | ||||||
| 12/07/2021 | Merck Sharp & Dohme Corporation | LENVIMA (Drug) | Consulting Fee | Cash or cash equivalent | $5,390.00 | General |
| Category: ONCOLOGY | ||||||
| 12/07/2021 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $2,730.00 | General |
| Category: ONCOLOGY | ||||||
| 12/07/2021 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $2,235.00 | General |
| Category: ONCOLOGY | ||||||
| 12/07/2021 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $280.00 | General |
| Category: ONCOLOGY | ||||||
| 11/05/2021 | Merck Sharp & Dohme Corporation | LENVIMA (Drug) | Consulting Fee | Cash or cash equivalent | $4,200.00 | General |
| Category: ONCOLOGY | ||||||
| 11/05/2021 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $3,780.00 | General |
| Category: ONCOLOGY | ||||||
| 11/05/2021 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $3,710.00 | General |
| Category: ONCOLOGY | ||||||
| 11/05/2021 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $2,520.00 | General |
| Category: ONCOLOGY | ||||||
| 11/05/2021 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $720.00 | General |
| Category: ONCOLOGY | ||||||
| 10/06/2021 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $6,300.00 | General |
| Category: ONCOLOGY | ||||||
| 10/06/2021 | Merck Sharp & Dohme Corporation | LENVIMA (Drug) | Consulting Fee | Cash or cash equivalent | $3,920.00 | General |
| Category: ONCOLOGY | ||||||
| 10/06/2021 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $2,520.00 | General |
| Category: ONCOLOGY | ||||||
| 10/06/2021 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $1,685.00 | General |
| Category: ONCOLOGY | ||||||
| 10/06/2021 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $770.00 | General |
| Category: ONCOLOGY | ||||||
| 09/03/2021 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $5,250.00 | General |
| Category: ONCOLOGY | ||||||
| 09/03/2021 | Merck Sharp & Dohme Corporation | LENVIMA (Drug) | Consulting Fee | Cash or cash equivalent | $3,850.00 | General |
| Category: ONCOLOGY | ||||||
| 09/03/2021 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $1,050.00 | General |
| Category: ONCOLOGY | ||||||
| 09/03/2021 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $770.00 | General |
| Category: ONCOLOGY | ||||||
| 09/03/2021 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $315.00 | General |
| Category: ONCOLOGY | ||||||
| 08/02/2021 | Merck Sharp & Dohme Corporation | LENVIMA (Drug) | Consulting Fee | Cash or cash equivalent | $7,490.00 | General |
| Category: ONCOLOGY | ||||||
| 08/02/2021 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $7,000.00 | General |
| Category: ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Phase III Nivo Ipi vs Placebo in Adjuvant RCC | E.R. Squibb & Sons, L.L.C. | $59,010 | 4 |
| Phase III Nivo Ipi vs Placebo in Adjuvant RCC - A Phase 3 Randomized, Double-Blind Study of Nivolumab Monotherapy or Nivolumab Combined with Ipilimumab vs Placebo in Participants with Localized Renal Cell Carcinoma Who Underwent Radical or Partial Nephrec | E.R. Squibb & Sons, L.L.C. | $45,515 | 1 |
| Phase III Nivo+Ipi vs Placebo in Adjuvant RCC (Part B FA) - A Phase 3 Randomized, Double-Blind Study of Nivolumab Monotherapy or Nivolumab Combined with Ipilimumab vs Placebo in Participants with Localized Renal Cell Carcinoma Who Underwent Radical or Par | E.R. Squibb & Sons, L.L.C. | $12,460 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 27 | 1,733 | 22,249 | $1.6M | $125,392 |
| 2022 | 24 | 1,160 | 14,909 | $1.0M | $84,384 |
| 2021 | 21 | 896 | 7,202 | $598,600 | $59,039 |
| 2020 | 17 | 674 | 5,112 | $520,710 | $53,656 |
Total Patients
4,463
Total Services
49,472
Medicare Billing
$322,471
Procedure Codes
117
All Medicare Procedures & Services
117 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 74177 | Ct scan of abdomen and pelvis with contrast | Office | 2023 | 127 | 134 | $417,952 | $34,538 | 8.3% |
| 74178 | Ct scan of abdomen and pelvis before and after contrast | Office | 2023 | 51 | 51 | $184,046 | $14,501 | 7.9% |
| 74177 | Ct scan of abdomen and pelvis with contrast | Facility | 2023 | 144 | 149 | $69,285 | $10,264 | 14.8% |
| 71260 | Ct scan of chest with contrast | Office | 2023 | 94 | 102 | $274,300 | $9,558 | 3.5% |
| 74176 | Ct scan of abdomen and pelvis without contrast | Office | 2023 | 56 | 60 | $157,370 | $8,959 | 5.7% |
| 74176 | Ct scan of abdomen and pelvis without contrast | Facility | 2023 | 96 | 96 | $36,000 | $6,104 | 17.0% |
| 76770 | Complete ultrasound scan behind abdominal cavity | Office | 2023 | 43 | 43 | $72,713 | $3,692 | 5.1% |
| 93970 | Ultrasound study of arm or leg veins with compression and maneuvers | Facility | 2023 | 124 | 127 | $33,020 | $3,286 | 10.0% |
| 71260 | Ct scan of chest with contrast | Facility | 2023 | 70 | 72 | $21,600 | $3,085 | 14.3% |
| 76536 | Ultrasound scan of head and neck soft tissue | Office | 2023 | 35 | 35 | $25,865 | $2,993 | 11.6% |
| 71250 | Ct scan of chest without contrast | Office | 2023 | 27 | 29 | $61,786 | $2,472 | 4.0% |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | Office | 2023 | 193 | 20,665 | $48,356 | $2,399 | 5.0% |
| 71250 | Ct scan of chest without contrast | Facility | 2023 | 59 | 60 | $16,200 | $2,373 | 14.7% |
| 71275 | Ct scan of blood vessels of chest with contrast | Facility | 2023 | 30 | 30 | $18,450 | $2,114 | 11.5% |
| 74178 | Ct scan of abdomen and pelvis before and after contrast | Facility | 2023 | 24 | 24 | $12,960 | $1,869 | 14.4% |
| 76770 | Complete ultrasound scan behind abdominal cavity | Facility | 2023 | 68 | 69 | $13,110 | $1,857 | 14.2% |
| 74174 | Ct scan of blood vessels of abdomen and pelvis with contrast | Facility | 2023 | 21 | 21 | $14,700 | $1,794 | 12.2% |
| 76705 | Limited ultrasound scan of abdomen | Facility | 2023 | 68 | 70 | $10,850 | $1,592 | 14.7% |
| 76700 | Complete ultrasound scan of abdomen | Office | 2023 | 16 | 16 | $27,104 | $1,545 | 5.7% |
| 76705 | Limited ultrasound scan of abdomen | Office | 2023 | 22 | 22 | $24,222 | $1,541 | 6.4% |
| 93880 | Ultrasound of both sides of head and neck blood flow | Facility | 2023 | 40 | 40 | $14,400 | $1,182 | 8.2% |
| 93975 | Complete ultrasound of abdomen and pelvis artery and vein blood flow | Facility | 2023 | 23 | 23 | $5,635 | $1,046 | 18.6% |
| 93971 | Ultrasound study of one arm or leg veins with compression and maneuvers | Office | 2023 | 11 | 11 | $15,800 | $1,025 | 6.5% |
| 76700 | Complete ultrasound scan of abdomen | Facility | 2023 | 25 | 25 | $5,000 | $726.47 | 14.5% |
| 93971 | Ultrasound study of one arm or leg veins with compression and maneuvers | Facility | 2023 | 36 | 36 | $3,600 | $611.10 | 17.0% |
About Dr. Patrick O'kane, M.D
Dr. Patrick O'kane, M.D is a Diagnostic Radiology healthcare provider based in Philadelphia, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/09/2006. The National Provider Identifier (NPI) number assigned to this provider is 1578596672.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Patrick O'kane, M.D has received a total of $584,199 in payments from pharmaceutical and medical device companies, with $24.35 received in 2024. These payments were reported across 142 transactions from 3 companies. The most common payment nature is "Consulting Fee" ($467,190).
As a Medicare-enrolled provider, O'kane has provided services to 4,463 Medicare beneficiaries, totaling 49,472 services with total Medicare billing of $322,471. Data is available for 4 years (2020–2023), covering 117 distinct procedure/service records.
Ad
Practice Information
- Specialty Diagnostic Radiology
- Location Philadelphia, PA
- Active Since 07/09/2006
- Last Updated 07/23/2014
- Taxonomy Code 2085R0202X
- Entity Type Individual
- NPI Number 1578596672
Products in Payments
- KEYTRUDA (Biological) $269,425
- OPDIVO (Biological) $116,985
- LENVIMA (Drug) $95,165
- MK-1308 (Drug) $61,065
- PYLARIFY (Drug) $24.35
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Diagnostic Radiology Doctors in Philadelphia
Jill Langer, Md, MD
Diagnostic Radiology — Payments: $2.5M
Diagnostic Radiology $2.5M
Joan Prowda, Md, MD
Diagnostic Radiology — Payments: $1.7M
Diagnostic Radiology $1.7M
Lisa Jones, Md, MD
Diagnostic Radiology — Payments: $1.3M
Diagnostic Radiology $1.3M
Evan Siegelman, Md, MD
Diagnostic Radiology — Payments: $1.2M
Diagnostic Radiology $1.2M
Parvati Ramchandani, Md, MD
Diagnostic Radiology — Payments: $971,832
Diagnostic Radiology $971,832
Dr. Steven Finden, M.d, M.D
Diagnostic Radiology — Payments: $664,346
Diagnostic Radiology $664,346